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CASE LETTERSFig 1. A, Magnetic resonance imaging (MRI) study
showing hyperintense lesion at C3 level on T2-weighted
images with intense contrast enhancement after gadolin-
ium injection. B, MRI scan of cervical spinal cord 6 months
later. The demyelinating lesion has disappeared totally.Acute transverse myelitis during treatment
with etanercept for severe plaque psoriasis
To the Editor: Tumor necrosis factor alpha (TNF-)
inhibitors constitute a class of biologic treatments
used in the management of psoriasis. Although
these biologics have favored significant clinical
improvement, there have been concerns for
emerging side effects.1 We present a case of a patient
with no prior history of demyelinating disease, who
developed acute transverse myelitis (ATM) while
being treated for chronic plaque psoriasis and
psoriatic arthritis with etanercept.
A 40-year-old woman with a 12-year history of
psoriasis, treated with etanercept (50 mg weekly) for
21 months, presented with a 5-day history of
paresthesias and muscular weakness that began
over the lower extremities and gradually extended
to the abdomen. The patient did not complain of any
imbalance, gait disturbance, urinary or bowel
incontinence, or any change in mental status.
Neurologic examination revealed segmental sensory
dysfunction with bilateral loss of pain and
vibration sensation at levels C8-D1. The rest of the
examination was unremarkable. Cerebrospinal fluid
examination and laboratory results indicative of
infectious or autoimmune cause were negative.
Cranial magnetic resonance imaging (MRI) and
visual evoked potentials were normal. MRI of the
spinal cord revealed a hyperintense lesion at the
third cervical (C3) level on T2-weighted images with
intense contrast enhancement after gadolinium
injection (Fig 1, A). Diagnosis of ATM was rendered.
Etanercept was immediately discontinued and the
patient was given intravenous methylprednisolone
1000 mg/day for 5 days in hospital. She was
discharged with a short taper of prednisone, and
clinical and imaging evaluation at 6 months showed
complete resolution of ATM (Fig 1, B).
The patient was started on ustekinumab, a human
interleukin 12/23 monoclonal antibody. Treatment
was successful with clearing of erythematous
squamous lesions and no recurrence of neurologic
symptoms or demyelination.
TNF- drugs have been used for the treatment of
rheumatoid arthritis, psoriatic arthritis, psoriasis,
ankylosing spondylitis, juvenile chronic arthritis,
and Crohn’s disease. Several studies have raised the
possibility that TNF- inhibitors may be associated
with neurologic adverse events including central and
peripheral nervous system demyelination.2 In 2006,J AM ACAD DERMATOLSukal et al reported a case of demyelinating disease
in a patient with psoriasis treated with etanercept.3
Recently, Mahil et al published a review summarizing
clinical data extracted on 65 reported cases of central
nervous system demyelination in patients receiving
TNF- inhibitors.4
Ustekinumab is a fully human monoclonal anti-
body against IL12/23 p40 approved for the treatment
of moderate to severe plaque psoriasis. Targeting
IL12/23 pathway has been examined for multiple
sclerosis treatment in a phase 2 study.5
In our case, there was no clinical or laboratory
finding indicative of any disease as the cause of
ATM and given the temporal relationship, weJANUARY 2014 e17
Fig 1. Cutaneous intestinal metaplasia. Hematoxylin and
eosin (top). CK20 immunohistochemistry (bottom).
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e18 Lettersconsidered the possibility of an adverse effect to
etanercept. During follow-up, clinical indicators and
MRI findings showed amelioration upon cessation of
treatment. At present, the patient remains under
treatment with ustekinumab at regular doses and
maintains good clinical response without develop-
ment of severe adverse effects.
Given the uncertainty in this area, it seems
reasonable to avoid the use of anti-TNF- agents
and offer an alternative regimen in patients with a
personal or family history of demyelinating disease.
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To the Editor: More than 70% of people with surgi-
cally induced intestinal stomas experience peristo-
mal skin complications, including contact reactions,
malignant neoplasms, preexisting skin diseases,infections, pyoderma gangrenosum, and other ul-
cerations.1 However, to our knowledge, there has
been only 1 reported case in the literature describing
a peristomal skin ulcer with scattered intestinal
tubular glands consistent with cutaneous intestinal
metaplasia,2 which is distinct from lesions of over-
granulation with intestinal metaplasia.1-3 We
describe the second case of cutaneous peristomal
intestinal metaplasia.
A 76-year-old Caucasian female with history of
ulcerative colitis, who had undergone a colectomy at
age 17 resulting in a right lower abdominal ileos-
tomy, presented to the dermatology department with
a 2-year history of persistent stinging and irritation at
the ileostomy site. She denied any changes in her
stoma care. Her ulcerative colitis had been well
controlled since the surgery.
On physical exam there was a red, superficially
erosive plaque extending along the cutaneous
border of the stoma, initially suggestive of irritant
dermatitis. Topical triamcinolone 0.1% ointment
every other day for 1 month was recommended at
that time, without improvement of the erosion or
symptoms on follow-up. Zinc oxide ointment mixed
with triamcinolone ointment was recommended for
an additional 3 months, but lack of significant
improvement on follow-up prompted a punch
biopsy of the plaque.
Histologic examination showed alternating
epidermis with granular layer and colonic-type
glandular mucosa, numerous goblet cells, and no
discernible Paneth cells (Fig 1). The glandular
elements expressed epithelial mucin, and by immu-
nohistochemistry showed strong, diffuse expression
